Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Mitsubishi sets up marketing network for cholesterol-binding agent; launch anticipated this year

Jan. 14, 1999

Asta Medica files for approval of LHRH antagonist and establishes marketing partnership

Jan. 14, 1999

European study establishes long-term efficacy and safety of alprostadil alfadex

Jan. 13, 1999

GelTex reports success with first- and second-generation cholesterol-lowering compounds

Jan. 13, 1999

Taiho synthesizes novel compounds for bone metabolism disorders

Jan. 13, 1999

New cysteine protease inhibitors from SB for osteoporosis, arthritis, etc.

Jan. 13, 1999

ATP citrate (pro-S)-lyase confirmed as potential therapeutic target in lipid disorders

Jan. 12, 1999

Milestone reached in Metabasis-Sankyo diabetes collaboration

Jan. 12, 1999

New market approvals for Zestril as Rx for renal complications of diabetes

Jan. 12, 1999

FDA approves world's smallest estrogen transdermal patch

Jan. 12, 1999

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...